David Roche of Quantum Strategy says a weaker dollar will drive 10-year yields to 5.5%, which will threaten the dollar's ...

For years, Roche has been increasing medicine production in the United States. That could pay off for the drug maker as ...

Seductive Reasoning,” a flop that preceded the Roches’ debut, has a fluctuating sonic palette, contributions from Paul Simon ...

Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo ...

Roche posted higher-than-expected first-quarter sales, driven by robust demand for its key drugs, as the company takes active ...

The pharma giant said the investment would create more than 12,000 jobs, as it joins rival Novartis in expanding its ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with artificial ...

The device helps identify NSCLC subjects who are likely to benefit from Daiichi Sankyo and AstraZeneca’s Datroway’s treatment ...

A recent report in The Times of India reveals that Roche may have profited immensely from risdiplam, a drug for spinal ...

If you’re set on sunscreen, it’s worth checking out the rest of the sale. Plenty of other Strategist-favorite brands are ...

Is Dot & Key as effective as La Roche-Posay sunscreen? Read this comparison guide and choose the best sunscreen brands to ...

Public health activists estimate Roche earned significantly more from risdiplam, a spinal muscular atrophy drug, than its ...